Hetero 
Welcome,         Profile    Billing    Logout  
 6 Products   1 Disease   6 Products   18 Trials   746 News 


«123456789101112»
  • ||||||||||  dolutegravir/lamivudine/tenofovir disoproxil fumarate / Cipla, Laurus Labs, Aurobindo, Viatris, Hetero, Macleods
    Enrollment closed:  Assess Therapeutic Efficacy and Emergence of HIV Drug Resistance Following Initiation of TLD (clinicaltrials.gov) -  Dec 28, 2022   
    P=N/A,  N=1339, Active, not recruiting, 
    Our findings do not support the need for initial dolutegravir dose adjustment in patients switching to TLD who failed first-line TEE. Recruiting --> Active, not recruiting
  • ||||||||||  Cimduo (lamivudine/tenofovir disoproxil fumarate) / Mylan, Celltrion, Aurobindo, Cipla, Hetero, Sun Pharma, Macleods
    Journal:  Characteristics and associated factors of blood lipid trajectories among HIV-infected patients receiving antiretroviral therapy (Pubmed Central) -  Dec 27, 2022   
    HIV-infected patients showed a dangerous trajectory of blood lipids after ART, which was significantly associated with the use of specific antiviral drugs such as AZT and LPV/r, treatment duration, baseline CD4, TC, TG levels and BMI. It is recommended to strengthen blood lipid monitoring and targeted intervention measure when HIV infected persons start antiviral treatment.
  • ||||||||||  Daklinza (daclatasvir) / BMS, NATDAC (daclatasvir) / NATCO, Hetero
    Retrospective data, Review, Journal:  Efficacy and Safety of Sofosbuvir-based Regimens in Hepatitis C Patients With Decompensated Cirrhosis: A Systematic Review and Meta-analysis. (Pubmed Central) -  Nov 22, 2022   
    Patients on SOF/velpatasvir±ribavirin achieved a significantly higher SVR (91.0%, 95% CI: 87.7-93.9) than that of SOF/ledipasvir±ribavirin [(86.3%, 95% CI: 84.6-87.8); p=0.004)], or on SOF/daclatasvir±ribavirin (82.4%, 95% CI: 78.2-86.2%; p<0.001)...There was no publication bias. The analysis found that 12 weeks of SOF/velpatasvir without ribavirin is the preferred therapy, with a significantly higher SVR compared with other SOF-based regimens in decompensated HCV patients.
  • ||||||||||  dolutegravir/lamivudine/tenofovir disoproxil fumarate / Cipla, Laurus Labs, Aurobindo, Viatris, Hetero, Macleods
    Trial completion:  ARTIST: Tenofovir-lamivudine-dolutegravir Combination as Second-line ART: a Randomised Controlled Trial (clinicaltrials.gov) -  Nov 8, 2022   
    P2,  N=192, Completed, 
    Fixed-dose combination DOR/TDF/3TC is equally effective and cost-saving compared to RPV/TDF/FTC from Russian vital and essential drugs list perspective. Active, not recruiting --> Completed
  • ||||||||||  Symfi (efavirenz/lamivudine/tenofovir disoproxil fumarate) / Mylan, dolutegravir/lamivudine/tenofovir disoproxil fumarate / Cipla, Laurus Labs, Aurobindo, Mylan, Hetero, Macleods
    Journal:  Six-Months Retention on Treatment and Attrition Risk Factors among People Living with HIV in Kibera Informal Settlement, Nairobi, Kenya. (Pubmed Central) -  Oct 22, 2022   
    To reduce further attrition in the early stages of HIV treatment, innovative strategies are needed to reach divorced and not married/single patients earlier and support them to remain on treatment. Efforts should also be made to further decentralize ART treatment to reduce costs and time associated with travelling to and from hospitals.
  • ||||||||||  dolutegravir/lamivudine/tenofovir disoproxil fumarate / Cipla, Laurus Labs, Aurobindo, Mylan, Hetero, Macleods
    Journal:  Antiretroviral Drug Resistance in HIV Sequences From People Who Inject Drugs and Men Who Have Sex With Men Across 21 Cities in India. (Pubmed Central) -  Oct 14, 2022   
    Patients experiencing virologic failure on first-line therapy switched blindly to tenofovir/lamivudine/dolutegravir may effectively be receiving dolutegravir monotherapy due to resistance to tenofovir and lamivudine. While dolutegravir is expected to have full activity in the majority of patients in India, follow-up is needed to understand how resistance may affect long-term outcomes.
  • ||||||||||  Symfi (efavirenz/lamivudine/tenofovir disoproxil fumarate) / Mylan, dolutegravir/lamivudine/tenofovir disoproxil fumarate / Cipla, Laurus Labs, Aurobindo, Mylan, Hetero, Macleods, dolutegravir/emtricitabine/tenofovir alafenamide (DTG/FTC/TAF) / Mylan
    Long-term risks of clinical obesity in the ADVANCE, NAMSAL and VISEND trials () -  Oct 4, 2022 - Abstract #HIVGlasgow2022HIV_Glasgow_274;    
    Across three randomised trials in 2867 patients, the risks of clinical obesity were significantly higher for DTG-based treatment, especially when combined with TAF/FTC. The adverse consequences of clinical obesity (e.g. diabetes, myocardial infarction) need to be factored into decisions on starting or switching to TAF/FTC/DTG, especially if already overweight at baseline.
  • ||||||||||  Prezista (darunavir) / J&J, dolutegravir/lamivudine/tenofovir disoproxil fumarate / Cipla, Laurus Labs, Aurobindo, Mylan, Hetero, Macleods
    Clinical, Retrospective data, Clinical Trial,Phase III, Journal:  Adaption of an ongoing clinical trial to quickly respond to gaps in changing international recommendations: the experience of DEFT. (Pubmed Central) -  Aug 9, 2022   
    At inception, it compared a standard of care of boosted darunavir with two nucleos(t)ide reverse transcriptase inhibitors (NRTIs) to the novel NRTI-sparing regimen of boosted darunavir with dolutegravir...Around the time of implementation, the World Health Organization updated its treatment guidelines and recommended scaling up tenofovir disoproxil fumarate-lamivudine-dolutegravir (TLD)...The optimal strategy was deemed to be the addition of a third arm, arriving retrospectively at a simplified multi-arm multi-stage clinical trial design to achieve statistical validity. The DEFT study maintains additional value in a quickly evolving second-line ART strategy allowed by the progress in global access to ART.
  • ||||||||||  dolutegravir/lamivudine/tenofovir disoproxil fumarate / Cipla, Laurus Labs, Aurobindo, Mylan, Hetero, Macleods
    WIDESPREAD PRIMARY GASTROINTESTINAL KAPOSI’S SARCOMA (Science Lounge) -  Jul 20, 2022 - Abstract #UEGW2022UEGW_2663;    
    Staging exams (thoracic, abdominal and pelvic CT scan and positron-emitting tomography) did not describe other suspicious lesions. The patient started antiretroviral therapy with tenofovir/lamivudine/dolutegravir and is currently under systemic chemotherapy with pegylated doxorrubicin.
  • ||||||||||  dolutegravir/lamivudine/tenofovir disoproxil fumarate / Cipla, Laurus Labs, Aurobindo, Mylan, Hetero, Macleods
    Journal:  Transitioning women to first-line preferred TLD regimen is lagging in Sub-Saharan Africa. (Pubmed Central) -  Jul 5, 2022   
    The patient started antiretroviral therapy with tenofovir/lamivudine/dolutegravir and is currently under systemic chemotherapy with pegylated doxorrubicin. Despite TLD being the WHO's preferred regimen since 2019, transition of women to potentially lifesaving TLD has been slower than men at certain clinical sites even after accounting for local eligibility criteria.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare, Vemlidy (tenofovir alafenamide) / Gilead
    Safety outcomes among HIV-1 positive Zambian adults receiving Tenofovir Alafenamide combined with Dolutegravir: results from the VISEND clinical trial () -  Jun 19, 2022 - Abstract #AIDS2022AIDS_3274;    
    The VISEND trial is a 144 week, randomized, open label, phase 3 noninferiority study in which weenrolled HIV-1 positive Zambian adults individuals who were receiving TDF/lamivudine (3TC) /efavirenz (EFV) or nevirapine (NVP) ART. Individuals on TAF/FTC/DTG had better renal and bone safety profiles whereas pregnancy outcomes were comparable in both groups.TAFED was associated with increased weight gain.Tenofovir alafenamide offers a choice for an ARV with balancedoptimal efficacy and potential for improved long-term safety among HIV positive individuals on ART.However,long term follow up is needed to ascertain metabolic complications in women.
  • ||||||||||  Pifeltro (doravirine) / Merck (MSD)
    Journal:  Doravirine/tenofovir disoproxyl fumarate/lamivudine-induced alopecia: A case report. (Pubmed Central) -  Jun 14, 2022   
    The association between the episode of alopecia and DOR/TDF/3TC was scored as probable according to the Naranjo causality scale. We concluded that alopecia was probably related to DOR but whether it is self-limiting, cannot be predicted at this stage.
  • ||||||||||  pegcetacoplan intravitreal (APL-2 intravitreal) / Apellis
    Review, Journal:  Novel approach to antiangiogenic factors in age-related macular degeneration therapy. (Pubmed Central) -  May 24, 2022   
    Among the directions in dry AMD treatment, the most promising are complement cascade inhibitors and complement cascade targeted gene therapy. In the article we outline the main directions in up-to-date experimental and practical approaches to wet and dry AMD therapy with the emphasis on antiangiogenic factors and gene therapy focused on the inhibition of pathological angiogenesis.
  • ||||||||||  dolutegravir/lamivudine/tenofovir disoproxil fumarate / Cipla, Laurus Labs, Aurobindo, Viatris, Hetero, Macleods
    Enrollment closed:  ARTIST: Tenofovir-lamivudine-dolutegravir Combination as Second-line ART: a Randomised Controlled Trial (clinicaltrials.gov) -  May 16, 2022   
    P2,  N=192, Active, not recruiting, 
    Future investigations should confirm the findings of this study, and more research into the effects of weight gain in these people is required. Recruiting --> Active, not recruiting
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Persistent low-level viremia in the era of dolutegravir in four African countries () -  May 12, 2022 - Abstract #AIDS2022AIDS_2548;    
    In this analysis, we included participants who were taking tenofovir/lamivudine/dolutegravir (TLD) for at least three months and had two subsequent VL measurements; we used the two most recent VL measurements. Studies to investigate associations with unsuppressed and pLLV are needed in these populations, including documentation of differences in viral genomics (e.g., viral subtypes and drug resistance mutations) and local participant demographic factors associated with adherence.